Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$137.35 USD
+2.41 (1.79%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $135.23 -2.12 (-1.54%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth A Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Krystal Biotech, Inc. has a market cap of $3.90B, which represents its share price of $134.94 multiplied by its outstanding shares number of 28.90M. As a mid-cap company, KRYS's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
KRYS 137.35 +2.41(1.79%)
Will KRYS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KRYS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KRYS
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook
Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates
KRYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
Other News for KRYS
What 8 Analyst Ratings Have To Say About Krystal Biotech
Chardan Capital Maintains Buy Rating for Krystal Biotech (KRYS) | KRYS Stock News
Citigroup Maintains Neutral Rating on KRYS, Lowers Price Target | KRYS Stock News
Krystal Biotech Inc (KRYS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results